ID   22Rv1-CabR1
AC   CVCL_A6PG
DR   cancercelllines; CVCL_A6PG
DR   Wikidata; Q107113178
RX   PubMed=31799745;
CC   Population: Caucasian.
CC   Characteristics: Established from xenografts that were obtain by subcutaneously injecting 22Rv1 cells into the flanks of 8 weeks old, athymic male BALB/c nude mice and treating them with cabazitaxel (PubMed=31799745).
CC   Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel.
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1045 ! 22Rv1
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=31799745; DOI=10.1002/pros.23935;
RA   Ylitalo E.B., Thysell E., Thellenberg-Karlsson C., Lundholm M.,
RA   Widmark A., Bergh A., Josefsson A., Brattsand M., Wikstrom P.;
RT   "Marked response to cabazitaxel in prostate cancer xenografts
RT   expressing androgen receptor variant 7 and reversion of acquired
RT   resistance by anti-androgens.";
RL   Prostate 80:214-224(2020).
//